vices will continue to be used off-label due to the lack of approved devices for specific indications. Over the next few years, it is expected that more indication-specific stents will emerge in Japan to meet the growing demand for peripheral vascular stenting in the carotid, renal, and other vascular indications, including the lower extremities."
MRG's new report, Japanese Markets for Peripheral Vascular Devices 2010, provides critical insight into emerging trends that will fuel market growth for peripheral vascular stents, percutaneous transluminal angioplasty balloon catheters, embolic protection devices, inferior vena cava filters, aortic stent grafts, synthetic surgical grafts, and accessory devices through 2014. With detailed analysis of procedures, units, average selling prices, revenues, and competitive dynamics, this report will allow you to identify opportunities, formulate meaningful marketing strategies, and track your competitors.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at
Page: 1 2 3 Related medicine technology :1
|SOURCE Millennium Research Group|
Copyright©2009 PR Newswire.
All rights reserved
. Japanese Cancer Patients Will Have Access to Compensator-Based IMRT with Opening of .decimal, Inc. Office in Tokyo and Hiring of Key Personnel2
. BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical3
. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research4
. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH5
. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents6
. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research7
. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health8
. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent9
. Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 201310
. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent11
. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas